Quantcast
Last updated on April 23, 2014 at 12:38 EDT

Latest pharmaceutical industry Stories

2014-04-16 08:30:45

ALBANY, New York, April 16, 2014 /PRNewswire/ -- ResearchMoz.us includes new market research report "The Pharmaceutical Market [http://www.researchmoz.us/pharmaceutical-market-reports-38.html ]: Greece, Denmark, Bahrain, Sri Lanka and Czech Republic "to its huge collection of research reports. The macroenvironment for the Danish pharmaceutical industry is improving.The centre-left coalition, of the Social Democratic Party, the Socialist People's Party and the Social...

2014-04-16 08:27:53

Analysis points to three potential blockbusters: Sovaldi, Anoro Ellipta and Idelalisib entering market this year PHILADELPHIA, April 16, 2014 /PRNewswire/ -- The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, released its annual forecast of the leading drugs to watch in 2014, including three potential blockbuster treatments anticipated to attain more than $1 billion in sales through...

2014-04-16 04:22:03

AMSTERDAM, April 16, 2014 /PRNewswire/ -- Responsibilities will include widening the brand's global reach and continuing CPhI Worldwide event expansion CPhI Worldwide [http://www.cphi.com ], part of UBM Live, has announced the appointment of Rutger Oudejans to the role of Brand Director of the UBM Pharma Portfolio. Central to the role is responsibility for the strategic development of UBM's Pharmaceutical brands (CPhI, ICSE, Inno-Pack...

2014-04-15 23:15:47

Takeda pharmaceutical company and marketing partner Eli Lilly have now been ordered by a Federal Court to pay for a Plaintiff's cancer injuries in connection with the drug Actos. A jury rewarded large punitive damages after they were instructed that they could infer that destroyed information implicated the drug Actos with Cancer. Commack, NY (PRWEB) April 15, 2014 Since entering the market in 1999, Actos has been Takeda’s most explosive selling drug, hitting global sales of over...

2014-04-15 23:08:01

Insulated Products Corp. utilizes disruptive technology that allows cold chain shippers to save money and protect the thermal integrity of cold shipping products. Los Angeles, CA (PRWEB) April 15, 2014 Insulated Products Corp. is changing the world of insulated shipping with the revolutionary Greenliner thermal packing product that saves them money and space. Industry maverick Charles Veiseh utilized a new disruptive technology to create the innovative Greenliner collapsible insulation...

2014-04-15 12:30:41

Market Access Challenges for Sanofi/Genzyme's Aubagio Highlight the Hurdles New Multiple Sclerosis Agents Face in Europe, According to Findings from Decision Resources Group BURLINGTON, Mass., April 15, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed neurologists in France, Germany, Italy, Spain, and the United Kingdom (EU5) project that 16 percent of their diagnosed relapsing-remitting multiple sclerosis (MS) patients on average will receive Biogen Idec's Tecfidera within...

2014-04-15 12:30:09

PITTSBURGH, April 15, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today confirmed that it and its partner Famy Care Ltd. have entered into a settlement and license agreement with Warner Chilcott Company, LLC, settling the parties' litigation in connection with Mylan's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for Norethindrone and Ethinyl Estradiol Chewable Tablets 0.8 mg/0.025 mg and Ferrous Fumarate Chewable Tablets. This...

2014-04-15 08:30:06

Purchase adds global regulatory writing and submission services to Certara's drug development consulting expertise NEW YORK, April 15, 2014 /PRNewswire/ -- Arsenal Capital Partners, a leading New York based private equity firm that invests in middle market healthcare, specialty industrial, and financial services companies, announced today the acquisition of Synchrogenix, the leading regulatory writing and related services firm. Synchrogenix provides services to pharmaceutical,...

2014-04-15 08:29:42

DUBLIN, April 15, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it has entered into an agreement with Mylan Inc. and Famy Care Ltd. to settle all outstanding patent litigation related to Mylan's generic version of Generess(®) FE (norethindrone, ethinyl estradiol and ferrous fumarate chewable tablets). Under the terms of the agreement, Actavis will grant Mylan a license to market its generic version of Generess(®) FE under its pending Abbreviated New Drug...

2014-04-15 08:28:24

DUBLIN, Apr. 15, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/6zn3pr/global_microrna ) has announced the addition of the "Global MicroRNA Market Report" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) The analysts forecast the Global MicroRNA market to grow at a CAGR of 17.51 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in microRNA research funding....